Lung Cancer
Filters
Regorafenib (LuciRegor) 40mg*28's | Lucius Laos Generic | GLT
LuciRegor — Lucius Pharmaceuticals regorafenib 40mg 28 tablets for mCRC, GIST & HCC.
Lazertinib (Lazcluze) 80/240mg | Janssen US Originator | GLT
Janssen Biotech originator Lazcluze (lazertinib) 80mg & 240mg tablets, third-generation EGFR-TKI for EGFR-mutated NSCLC, US-sourced.
Lazertinib (Leclaza) 80mg | Yuhan Korea Originator | GLT
Yuhan originator Leclaza (lazertinib) 80mg x 84 tablets, the first Korean-developed third-generation EGFR-TKI for NSCLC.
Lazertinib (LuciLazer) 80mg | Lucius Laos Generic | GLT
LuciLazer (lazertinib) 80mg x 60 tablets by Lucius Pharmaceuticals Laos, cost-effective generic third-generation EGFR-TKI.
Pembrolizumab (Keytruda) 100mg/4mL | Japan PMDA-Approved PD-1 Inhibitor | GLT
PD-1 inhibitor for multiple cancers — Japan-sourced, PMDA-approved Keytruda at competitive global pricing
Pembrolizumab (Keytruda) 100mg/4mL & 50mg | US FDA-Approved PD-1 Inhibitor | GLT
PD-1 inhibitor for multiple cancers — US-sourced, FDA-approved Keytruda at competitive global pricing
Pembrolizumab (Keytruda) 100mg/4mL | Hong Kong Registered PD-1 Inhibitor | GLT
PD-1 inhibitor for multiple cancers — Hong Kong-registered Keytruda at competitive global pricing
Pemomab (Pembrolizumab) 100mg/4mL | Affordable PD-1 Inhibitor Biosimilar | GLT
PD-1 inhibitor biosimilar for multiple cancers — cost-effective pembrolizumab at accessible pricing
Kadcyla Ado-trastuzumab Emtansine (T-DM1) 100/160mg | Roche Switzerland Originator | GLT
Roche originator Kadcyla ado-trastuzumab emtansine (T-DM1) 100mg & 160mg vials, HER2-targeted ADC for HER2-positive breast...
UJVIRA Ado-trastuzumab Emtansine (T-DM1) 100/160mg | Zydus India Biosimilar | GLT
Zydus UJVIRA ado-trastuzumab emtansine (T-DM1) biosimilar 100mg & 160mg vials, world's first T-DM1 biosimilar ADC...
Ibtrozi (Taletrectinib) 200mg Capsules | ROS1 Inhibitor | GLT
Nuvation Bio next-generation ROS1 inhibitor for ROS1-positive NSCLC
Selpercatinib (Retevmo) 80mg — RET-Driven Cancer | China-Sourced | GLT
NMPA-approved RET inhibitor for RET fusion-positive NSCLC and thyroid cancer (China)
Ceritinib (Spexib) 150mg*150's | Novartis India Originator | GLT
Novartis's Indian-market ceritinib (Spexib) 150mg capsules, 150 per multipack for ALK-positive NSCLC — same originator...
Tagrisso (Osimertinib) 80mg*30 | AstraZeneca UK Originator | GLT
AstraZeneca UK originator osimertinib 80mg — the reference EGFR TKI for NSCLC
Tagrisso (Osimertinib) 80mg*30 | AstraZeneca China NMPA | GLT
China-Mainland Tagrisso 80mg — NMPA-approved, nationally reimbursed originator osimertinib
Ceritinib (Zykadia) 150mg*10's | Novartis Switzerland Originator | GLT
Novartis Switzerland originator Zykadia (ceritinib) 150mg capsules, 10-capsule starter pack for ALK-positive NSCLC.
Ceritinib (Zykadia) 150mg*150's | Novartis China-Sourced | GLT
Novartis China-sourced Zykadia (ceritinib) 150mg capsules, NMPA-approved & reimbursed for ALK-positive NSCLC.
Ceritinib (Noxalk) 150mg*90's | Natco India Generic | GLT
Noxalk — Natco Pharma India generic ceritinib 150mg, 90-capsule pack for ALK-positive NSCLC.
Tepmetko (Tepotinib) 225mg*60 | Merck KGaA Germany Originator | GLT
Merck KGaA Germany originator tepotinib 225mg — the first oral MET inhibitor for NSCLC
Tepmetko (Tepotinib) 225mg*60 | Merck KGaA China NMPA | GLT
China-Mainland Tepmetko 225mg — NMPA-approved, nationally reimbursed originator tepotinib
Sort
- Recommended
- Price: Low to High
- Price: High to Low
- Newest
- Best Selling